Drugs in R&D

Keyphrases

Publications

volume 24, number 2, 2024

Yanrong Wang, Yuanyuan He, Weihong Li, Hongmin Li, Liyuan Tang, Xinya Dai, Yingzi Pei, Lijing Gao
Evaluation of Ornidazole Tablets Bioequivalence in Chinese Healthy Participants Under Fasted and Fed Conditions Using Pharmacokinetic Parameters. Drugs in R&D 24 (2) (2024)
Henriette Kuehne, Janice M Davis, LeeAnne Merewether, Matthew McQueen, Elizabeth Valentine, Glen Young, Benjamin T Andrews, Dimitri Diaz, Karen J Miller
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim. Drugs in R&D 24 (2) (2024)
Anita Moein, Jin Y Jin, Matthew R Wright, Bruno Alicke, Harvey Wong
Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor. Drugs in R&D 24 (2) (2024)
Stefania Bellino, Anna La Salvia
The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making. Drugs in R&D 24 (2) (2024)
Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, Yoko Furukawa-Hibi, Akimichi Morita
Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma. Drugs in R&D 24 (2) (2024)
Yingxia He, Jie Wang, Fang Yao, Pan Lu, Yafang Xie, Xiuwen Li, Qiangwei Liu, Yang Liu, Dan Cao, Jun Liang, Dan Tian, Guan Liu
Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study. Drugs in R&D 24 (2) (2024)
Timothy J Turner, Pricilla Brun, Ross C Gruber, Dimitry Ofengeim
Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis. Drugs in R&D 24 (2) (2024)
Ina Lami, Andrew J Wiemer
Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations. Drugs in R&D 24 (2) (2024)
Richard Langford, Eugene R Viscusi, Adelaida Morte, Jesús Cebrecos, Mariano Sust, José María Giménez-Arnau, Oscar A deLeon-Casasola
Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials. Drugs in R&D 24 (2) (2024)
Xiaojie Wu, Jicheng Yu, Beikang Ge, Jeffrey Wang, Xiaoran Han, Chunye Zhang, Xiaomeng Mao, Hindu Kalluru, Candace Bramson, Steven G Terra, Jing Liu
A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides. Drugs in R&D 24 (2) (2024)
Yingxia He, Jie Wang, Fang Yao, Pan Lu, Yafang Xie, Xiuwen Li, Qiangwei Liu, Yang Liu, Dan Cao, Jun Liang, Dan Tian, Guan Liu
Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study. Drugs in R&D 24 (2) (2024)
Brian P Mulherin, Michael Yeh, Mohammed Al-Adhami, David Dingli
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. Drugs in R&D 24 (2) (2024)
Jin-Woo Park, Hyewon Chung, Jong-Min Kim, Na Young Kim, Sung Hee Hong, Kyoung-Ah Kim, Ji-Young Park
Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants. Drugs in R&D 24 (2) (2024)
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei, Stefano Comai, Franco Folli, Marco Pappagallo, Clotilde Guidetti, Charles E Inturrisi, Paolo L Manfredi
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment. Drugs in R&D 24 (2) (2024)
Brian P Mulherin, Michael Yeh, Mohammed Al-Adhami, David Dingli
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. Drugs in R&D 24 (2) (2024)
Kaiqin Chen, Yongtai Chen, Hesen Huang
Exploring the Relationship Between Atorvastatin and Memory Loss: A Comprehensive Analysis Integrating Real-World Pharmacovigilance and Mendelian Randomization. Drugs in R&D 24 (2) (2024)
Henriette Kuehne, Janice M Davis, LeeAnne Merewether, Matthew McQueen, Elizabeth Valentine, Glen Young, Benjamin T Andrews, Dimitri Diaz, Karen J Miller
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim. Drugs in R&D 24 (2) (2024)
Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, Yoko Furukawa-Hibi, Akimichi Morita
Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma. Drugs in R&D 24 (2) (2024)
Stefania Bellino, Anna La Salvia
The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making. Drugs in R&D 24 (2) (2024)
Olivia Lim, Eamonn Maher, Daniel D Miller
PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report. Drugs in R&D 24 (2) (2024)
Zhendong Chen, Max Taubert, Chunli Chen, Jana Boland, Qian Dong, Muhammad Bilal, Charalambos Dokos, Bertil Wachall, Manfred Wargenau, Bernhard Scheidel, Martin H J Wiesen, Elke Schaeffeler, Roman Tremmel, Matthias Schwab, Uwe Fuhr
A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes. Drugs in R&D 24 (2) (2024)
Kazuo Mishima, Kenichi Fujimoto, Akira Endo, Mika Ishii
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo ® Tablets. Drugs in R&D 24 (2) (2024)
Yingrong Chen, Libing Ye, Jue Mei, Mengli Tian, Min Xu, Qiuyue Jin, Xiang Yu, Shuixin Yang, Jie Wang
Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Drugs in R&D 24 (2) (2024)
Jin-Woo Park, Hyewon Chung, Jong-Min Kim, Na Young Kim, Sung Hee Hong, Kyoung-Ah Kim, Ji-Young Park
Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants. Drugs in R&D 24 (2) (2024)
Zhendong Chen, Max Taubert, Chunli Chen, Jana Boland, Qian Dong, Muhammad Bilal, Charalambos Dokos, Bertil Wachall, Manfred Wargenau, Bernhard Scheidel, Martin H J Wiesen, Elke Schaeffeler, Roman Tremmel, Matthias Schwab, Uwe Fuhr
A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes. Drugs in R&D 24 (2) (2024)
Veshni Pillay-Fuentes Lorente, Jacinta Nwamaka Nwogu, Britta Steffens, Dominic Stefan Bräm, Viviane P Sprecher, Daniela Hofmann, Michael Buettcher, Goonaseelan 'Colin' Pillai, Samer Mouksassi, Jean Coulibaly, Marc Pfister, Jennifer Keiser
Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d'Ivoire. Drugs in R&D 24 (2) (2024)
Yanrong Wang, Yuanyuan He, Weihong Li, Hongmin Li, Liyuan Tang, Xinya Dai, Yingzi Pei, Lijing Gao
Evaluation of Ornidazole Tablets Bioequivalence in Chinese Healthy Participants Under Fasted and Fed Conditions Using Pharmacokinetic Parameters. Drugs in R&D 24 (2) (2024)
Zhendong Chen, Max Taubert, Chunli Chen, Jana Boland, Qian Dong, Muhammad Bilal, Charalambos Dokos, Bertil Wachall, Manfred Wargenau, Bernhard Scheidel, Martin H J Wiesen, Elke Schaeffeler, Roman Tremmel, Matthias Schwab, Uwe Fuhr
A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes. Drugs in R&D 24 (2) (2024)
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei, Stefano Comai, Franco Folli, Marco Pappagallo, Clotilde Guidetti, Charles E Inturrisi, Paolo L Manfredi
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment. Drugs in R&D 24 (2) (2024)
Yingrong Chen, Libing Ye, Jue Mei, Mengli Tian, Min Xu, Qiuyue Jin, Xiang Yu, Shuixin Yang, Jie Wang
Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Drugs in R&D 24 (2) (2024)
Yanrong Wang, Yuanyuan He, Weihong Li, Hongmin Li, Liyuan Tang, Xinya Dai, Yingzi Pei, Lijing Gao
Evaluation of Ornidazole Tablets Bioequivalence in Chinese Healthy Participants Under Fasted and Fed Conditions Using Pharmacokinetic Parameters. Drugs in R&D 24 (2) (2024)
Anita Moein, Jin Y Jin, Matthew R Wright, Bruno Alicke, Harvey Wong
Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor. Drugs in R&D 24 (2) (2024)
Veshni Pillay-Fuentes Lorente, Jacinta Nwamaka Nwogu, Britta Steffens, Dominic Stefan Bräm, Viviane P Sprecher, Daniela Hofmann, Michael Buettcher, Goonaseelan 'Colin' Pillai, Samer Mouksassi, Jean Coulibaly, Marc Pfister, Jennifer Keiser
Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d'Ivoire. Drugs in R&D 24 (2) (2024)
Kazuo Mishima, Kenichi Fujimoto, Akira Endo, Mika Ishii
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo ® Tablets. Drugs in R&D 24 (2) (2024)
Kaiqin Chen, Yongtai Chen, Hesen Huang
Exploring the Relationship Between Atorvastatin and Memory Loss: A Comprehensive Analysis Integrating Real-World Pharmacovigilance and Mendelian Randomization. Drugs in R&D 24 (2) (2024)
Timothy J Turner, Pricilla Brun, Ross C Gruber, Dimitry Ofengeim
Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis. Drugs in R&D 24 (2) (2024)
Xiaojie Wu, Jicheng Yu, Beikang Ge, Jeffrey Wang, Xiaoran Han, Chunye Zhang, Xiaomeng Mao, Hindu Kalluru, Candace Bramson, Steven G Terra, Jing Liu
A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides. Drugs in R&D 24 (2) (2024)
Nada M El Ezaby, Entsar A Saad, Mohamed A El Basuni
Acetylsalicylic Acid with Ascorbate: A Promising Combination Therapy for Solid Tumors. Drugs in R&D 24 (2) (2024)
Richard Langford, Eugene R Viscusi, Adelaida Morte, Jesús Cebrecos, Mariano Sust, José María Giménez-Arnau, Oscar A deLeon-Casasola
Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials. Drugs in R&D 24 (2) (2024)
Olivia Lim, Eamonn Maher, Daniel D Miller
PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report. Drugs in R&D 24 (2) (2024)
Nada M El Ezaby, Entsar A Saad, Mohamed A El Basuni
Acetylsalicylic Acid with Ascorbate: A Promising Combination Therapy for Solid Tumors. Drugs in R&D 24 (2) (2024)
Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, Yoko Furukawa-Hibi, Akimichi Morita
Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma. Drugs in R&D 24 (2) (2024)
Brian P Mulherin, Michael Yeh, Mohammed Al-Adhami, David Dingli
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. Drugs in R&D 24 (2) (2024)
Jin-Woo Park, Hyewon Chung, Jong-Min Kim, Na Young Kim, Sung Hee Hong, Kyoung-Ah Kim, Ji-Young Park
Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants. Drugs in R&D 24 (2) (2024)
Olivia Lim, Eamonn Maher, Daniel D Miller
PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report. Drugs in R&D 24 (2) (2024)
Richard Langford, Eugene R Viscusi, Adelaida Morte, Jesús Cebrecos, Mariano Sust, José María Giménez-Arnau, Oscar A deLeon-Casasola
Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials. Drugs in R&D 24 (2) (2024)
Kazuo Mishima, Kenichi Fujimoto, Akira Endo, Mika Ishii
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo ® Tablets. Drugs in R&D 24 (2) (2024)
Ina Lami, Andrew J Wiemer
Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations. Drugs in R&D 24 (2) (2024)
Yingrong Chen, Libing Ye, Jue Mei, Mengli Tian, Min Xu, Qiuyue Jin, Xiang Yu, Shuixin Yang, Jie Wang
Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Drugs in R&D 24 (2) (2024)
Anita Moein, Jin Y Jin, Matthew R Wright, Bruno Alicke, Harvey Wong
Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor. Drugs in R&D 24 (2) (2024)